- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept. (Pubmed Central) - Mar 8, 2022
A relatively high proportion of polyp regression was observed in the IVA group (63%) compared with the IVC group (55%) via OCTA. Visual and anatomic outcomes were significantly improved in both IVA and IVC groups, but the results suggest a potentially superior short-term response in the IVA group.
- |||||||||| LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Biomarker, Clinical, Journal: Proteomic changes of aqueous humor in proliferative diabetic retinopathy patients treated with different intravitreal anti-VEGF agents. (Pubmed Central) - Mar 5, 2022
In summary, we discovered that ALDH3A1 was a previously unreported protein that was related to angiogenesis and was differentially expressed in the three anti-VEGF treatment groups, suggesting that it may be a new target for PDR therapy. The described proteomic changes in the AH of PDR patients treated with different anti-VEGF agents provide novel targets which may explain the heterogeneity of anti-VEGF treatment responses in these patients, providing a robust foundation for future studies of PDR pathogenesis.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Baseline predictors of short-term visual outcomes after intravitreal conbercept injection for neovascular age-related macular degeneration. (Pubmed Central) - Feb 17, 2022
The modified trabeculectomy and the implantation of EX-PRESS drainage device have clinical application value in reducing IOP and postoperative complications of refractory NVG. Poor recovery of patients after intravitreal conbercept injection may be related to the number of subretinal hyperreflective dots, the state of external limiting membrane, baseline best-corrected visual acuity, and age, which may be used as predictors of short-term visual outcomes and should be fully evaluated before operation.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Pharma
Trial primary completion date: Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization (clinicaltrials.gov) - Feb 10, 2022
P=N/A, N=150, Recruiting,
The frequency of anti-VEGF therapy could be reduced to the most extent, and the possibility of recurrence could be reduced as well, resulting good economic benefits. Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
New trial, Real-world evidence, Real-world: Anti-VEGF in Real-world (clinicaltrials.gov) - Feb 2, 2022
P=N/A, N=1000, Recruiting,
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Low-dose rAAV-mediated inhibition of VEGF can treat neovascular pathologies without inducing retinal vasculitis. (Pubmed Central) - Feb 1, 2022
Here, we show that two out of four rAAV serotypes tested by intravitreal delivery to express the anti-VEGF drug conbercept lead to a dose-dependent vascular sheathing pathology that is characterized by immune cell infiltrates, reminiscent of vasculitis in humans...The data suggest that treatments of neovascular eye pathologies with rAAV-mediated expression of anti VEGF drugs can be developed safely. However, viral load needs to be adjusted to the tropisms of the serotype and the expression pattern of the promoter.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Changes of plasma nitric oxide, endothelin-1, and blood coagulation following intravitreal conbercept. (Pubmed Central) - Jan 28, 2022
Plasma levels of NO or ET-1 or VEGF did not significantly change from pre-injection levels. Our findings advanced the understanding of mechanism for systemic side effects associated with intravitreal anti-VEGF and emphasized paying more attention to higher risk of possible bleedings for patients following intravitreal conbercept.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma. (Pubmed Central) - Jan 28, 2022
P=N/A
We recommend intravitreal injections for patients in stages I and II, but for stage III, intracameral injection is better, and trabeculectomy with mitomycin C should be conducted within 2 days after injection to maximally reduce the risk of perioperative hyphema. Trial Registration: ClinicalTrials.gov, identifier NCT03154892.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Anti-inflammatory activities of a new VEGF blocker, Conbercept. (Pubmed Central) - Jan 27, 2022
Conbercept significantly inhibited xylene-induced ear edema. All results indicate that Conbercept exhibits significant inhibition of acute and chronic inflammation.
- |||||||||| Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi, Avastin (bevacizumab) / Roche
Clinical, Review, Journal, Adverse events: Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. (Pubmed Central) - Jan 20, 2022
Nonetheless, ocular adverse events following anti-VEGF therapy for myopic CNV may develop and these include worsening or new development of myopic traction maculopathy, increased risk of retinal detachment and progression of chorioretinal atrophy. Clinicians should be aware of these potential complications and evaluate them before and after anti-VEGF therapy.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Preclinical, Journal: A Study on the Drug Concentration in Fellow Eyes After Unilateral Intravitreal Injection of Conbercept Into New Zealand Rabbit Eyes. (Pubmed Central) - Dec 21, 2021
A peak concentration of 102.49 ng/ml was achieved in the venous serum 1 day after intravitreal injection of conbercept, which was 0.08 and 0.5% of those of the maximum conbercept concentrations in the vitreous humor and aqueous humor of the injected eye, respectively, and 41.5 and 41.8% of the maximum conbercept concentrations in the vitreous humor and aqueous humor of the non-injected eye, respectively. In conclusion, after intravitreal injection of 0.5 mg of conbercept into rabbit eyes, very small amounts of conbercept were detected in the fellow non-injected eyes and venous serum.
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal, HEOR: Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model. (Pubmed Central) - Dec 21, 2021
The sensitivity analysis showed the same findings, although the ICER is sensitive to the costs of this program. Under the current Chinese healthcare setting, conbercept is suitable and cost-effective in treatment of AMD, DME, and PM compared with ranibizumab.
- |||||||||| Review, Journal: Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Dec 16, 2021
Sustained-release anti-VEGF therapies include the ranibizumab Port Delivery System (in phase 3 studies), GB-102 (Phase 2b), OTX-TKI (phase 1), and Durasert (preclinical)...Genetic therapies in phase 1 studies include RGX-314 and ADVM-022, which introduce a viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory, potentially serving as a one-time treatment. Further investigation is warranted for drugs and delivery systems that hope to advance visual outcomes and reduce treatment burden of nAMD.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization in Nursing Women. (Pubmed Central) - Dec 16, 2021
After conbercept injection, VEGF levels in breast milk were slightly decreased and did not change significantly in the following week; levels recovered fully by 30 days post-treatment. Intravitreal injection of conbercept shows favorable effectiveness and safety in the treatment of idiopathic CNV in nursing women and does not result in a significant reduction in VEGF in human breast milk.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: AQUEOUS HUMOR CYTOKINE LEVELS AND REBOUND MACULAR EDEMA AFTER CONBERCEPT TREATMENT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION. (Pubmed Central) - Nov 24, 2021
Conbercept treatment influenced the concentrations of various inflammatory cytokines and reduced aqueous vascular endothelial growth factor and placental growth factor concentrations. Rebound ME may occur due to disruption of the balance between angiogenic and inflammatory cytokines and an accompanying excess of inflammatory cytokines but not angiogenic cytokines, after antivascular endothelial growth factor therapy.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: Efficacy of Conbercept in the Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia. (Pubmed Central) - Nov 10, 2021
The intravitreal injection of conbercept significantly reduced CRT and the CNV area, inhibited the leakage of CNV, improved the BCVA, increased the response of mfERG amplitude, and restored the retinal function. The intravitreal injection of conbercept can change the morphology and function of the macular in PM-CNV, which is safe and effective for the treatment of PM-CNV.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Retrospective data, Review, Journal: Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis. (Pubmed Central) - Oct 31, 2021
IVC is well-tolerated and effective for improving vision acuity and quantitative measures in fundus condition in patients with nAMD and DME compared with LP, IVT, and placebo, but gains comparable efficacy to IVR. However, well-designed, large-sample, and long-term evaluation of IVC shall be conducted in additional studies worldwide.
- |||||||||| Avastin (bevacizumab) / Roche, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept. (Pubmed Central) - Oct 20, 2021
There have not been many clinical trials that study conbercept as compared with other currently available anti-VEGF drugs. There is a need for large-scale, well-designed, randomized clinical trials to ensure its long-term safety and efficacy and to determine if it has any advantages over other anti-VEGF agents.
- |||||||||| Journal: New Anti-Vegf Drugs In Ophthalmology. (Pubmed Central) - Oct 9, 2021
This review focuses on 5 new anti-VEGF drugs in advanced stage of clinical development (i.e. phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and advantages of each drug compared to the available molecules are discussed in detail.
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Oct 8, 2021
Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Review, Journal: Pipeline therapies for neovascular age related macular degeneration. (Pubmed Central) - Oct 3, 2021
Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA)...Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics. (Pubmed Central) - Sep 14, 2021
A single-dose rAAV8-KH902 treatment at 8 × 10 genome copies (GCs) per cornea dramatically inhibited CoNV for an extended period of time in mouse CoNV models without adverse events, whereas the inhibition of CoNV by a single intrastromal administration of the conbercept drug lasted for only 10-14 days. Overall, our study demonstrated that the treatment of CoNV with a single dose of rAAV8-KH902 via intrastromal administration was safe, effective, and long lasting, representing a novel therapeutic strategy for CoNV.
- |||||||||| Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: A case report: pseudoxanthoma elasticum diagnosed based on ocular angioid streaks and the curative effect of Conbercept treatment. (Pubmed Central) - Aug 25, 2021
To the best of our knowledge, no publications are available on cases in which a vision loss and the normal visual function can be reverted by intravitreal injection with Conbercept. Although PXE is a disease with low incidence and thus no effective cure established, targeted symptomatic treatment can effectively retard the disease progression and improve visual function, such as intravitreal injection with Conbercept.
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments. (Pubmed Central) - Aug 11, 2021
The corticosteroids approach is mainly based on the employment of triamcinolone acetonide, dexamethasone and fluocinolone acetonide molecules...Furthermore, several new molecules are currently under investigation. Intravitreal drugs focus their activity on a wide range of therapeutic targets and are safe and efficacy in managing retinal diseases.
|
